Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 25 November 2017

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Hep C profile in US shows consequences of the disease are yet to come

The curious distribution and increase of Hep C reflects the aging of a cohort identified over 20 years ago, who, now in their 40s and 50s, mostly acquired Hep C by injecting drugs earlier in life, reports May's Annals of Internal Medicine.

News image

fiogf49gjkf04

An update to a large national health survey finds that the total number of people infected with Hepatitis C virus has not changed substantially between 1994 and 2002.

However, the most frequent age bracket of those infected has shifted from 30 to 39 in the earlier study to 40 to 49 in the current study.

Most infected people engaged in intravenous drug use in their youth.

These patients are now entering the age when the consequences of Hepatitis C infections, such as cirrhosis, liver cancer and kidney disease, begin.

Dr Gregory Armstrong and colleagues conducted a nationally representative household survey of a US civilian, noninstitutionalized population.

The team included 15,079 participants in the National Health and Nutrition Examination Survey between 1999 and 2002.

48% of anti-Hep C-positive patients reported a history of injecting drugs
Annals of Internal Medicine

All participants provided medical histories, and those who were 20 to 59 years of age provided histories of drug use and sexual practices.

Participants were tested for antibodies to Hepatitis C and Hepatitis C virus RNA, and their serum alanine aminotransferase levels were measured.

The investigative team found that the prevalence of anti-Hepatitis C in the US was almost 2%.

This equates to an estimated 4 million anti-Hepatitis C-positive persons nationwide.

The team noted that about 1%, or 3 million persons had chronic Hepatitis C infection.

Peak prevalence of anti-Hepatitis C was observed among persons 40 to 49 years of age.

A total of 48% of anti-Hepatitis C-positive persons between 20 and 59 years of age reported a history of injection drug use.

This is the strongest risk factor for Hepatitis C infection.

Of all persons reporting such a history, 83% had not used injection drugs for at least 1 year before the survey.

The team observed that other significant risk factors included 20 or more lifetime sex partners and blood transfusion before 1992.

Abnormal serum alanine aminotransferase levels were found in 59% of Hepatitis C RNA-positive persons.

A combination of these 3 characteristics identified 85% of Hepatitis C RNA-positive participants between 20 and 59 years of age.

Dr Armstrong's team commented, “Many Americans are infected with Hepatitis C.”

“Most were born between 1945 and 1964 and can be identified with current screening criteria.”

“History of injection drug use is the strongest risk factor for infection.”

Dr Jules Dienstag, editorial writer of Annals of Internal Medicine, adds, “The ‘curious distribution' of Hepatits C infection probably reflects the aging of the same cohort with HCV infection that was identified during the 1988-1994 survey”.

”These people, now in their 40s and 50s, acquired their infections primarily through injection drug use that began in the 1960s and peaked in the 1980s, a time of widespread experimentation with substances of abuse.”

"This cohort has lived with unrecognized Hepatitis C infection for several decades.”

“However, as they age, they are more likely to seek regular medical care and apply for life insurance, unearthing their Hepatitis C infection.”

Ann Int Med 2006: 144(10): 705-14
16 May 2006

Go to top of page Email this page Email this page to a colleague

 24 November 2017 
Osteoporotic fractures in Barrett's esophagus
 24 November 2017 
Center ERCP volume and procedure success
 24 November 2017 
Adipokines and IBD
 23 November 2017 
Pharmacological management of GERD
 23 November 2017 
Incidence of biopsy-verified celiac disease
 23 November 2017 
Distance travelling for rectal cancer outcomes
 22 November 2017 
Challenges of US-trained gastroenterologists when abroad
 22 November 2017 
Surgical treatment delays influence survival in colon cancer
 22 November 2017 
Golimumab in Crohn's disease
 21 November 2017 
Preoperative optimization in IBD patients
 21 November 2017 
Cholangiopathy in critically ill patients
 21 November 2017 
Prepregnancy obesity and maternal mortality
 20 November 2017 
Barriers to hepatitis C treatment
 20 November 2017 
Socioeconomic characteristics in diverticular disease
 20 November 2017 
Endoscopic indices of disease activity for Crohn’s
 17 November 2017 
Food elimination diets for treatment of adults with eosinophilic esophagitis
 17 November 2017 
PPI use and cognitive function in women
 17 November 2017 
Predicting microscopic colitis
 16 November 2017 
NAFLD-hepatocellular carcinoma and survival after orthotopic liver transplant
 16 November 2017 
Prepregnancy obesity and severe maternal morbidity
 16 November 2017 
Celiac disease screening in adult first-degree relatives
 15 November 2017 
Breastfeeding and the risk of IBD
 15 November 2017 
Predicting recurrence after curative rectal cancer surgery
 15 November 2017 
Medication nonadherence and health care costs
 14 November 2017 
Eosinophilic gastroenteritis and colitis
 14 November 2017 
HBV/HCV coinfection and cirrhosis
 14 November 2017 
Sexual dysfunction after rectal cancer surgery
 13 November 2017 
Genetic polymorphisms, fatty acids and ulcerative colitis
 13 November 2017 
Flares after immunomodulator withdrawal in Crohn's
 13 November 2017 
GI bleeding in patients taking non–vitamin K antagonist oral anticoagulants
 10 November 2017 
Thiopurines vs TNF and lymphoma risk in IBD
 10 November 2017 
Drug monitoring of anti-tumour necrosis factor therapy in IBD
 10 November 2017 
Treatment decisions for older patients with colorectal cancer
 09 November 2017 
Quality standards in upper gastrointestinal endoscopy
 09 November 2017 
Irradiated rectal cancer and chemoradiotherapy
 09 November 2017 
Environmental factors and IBD
 08 November 2017 
Prophylaxis of spontaneous bacterial peritonitis
 08 November 2017 
Optimal management of postoperative Crohn's disease
 07 November 2017 
Community Screening for Helicobacter pylori
 07 November 2017 
Early readmission in IBD patients
 07 November 2017 
Mesocolic excision for colon cancer
 06 November 2017 
Food elimination diet for children with eosinophilic esophagitis
 06 November 2017 
Biologic agents and obesity in children with IBD
 06 November 2017 
Liver cancer burden despite extensive use of antiviral agents
 03 November 2017 
Statins and mortality in chronic viral hepatitis
 03 November 2017 
Propofol for outpatient colonoscopy
 03 November 2017 
Asthma and IBD development
 02 November 2017 
Diverticulitis and emergency department burden
 02 November 2017 
Rural residence and risk of IBD
 02 November 2017 
Sexual functioning in Hep C
 01 November 2017 
Autoimmune pancreatitis in children
 01 November 2017 
Heartburn relief in adolescents with GERD
 31 October 2017 
Follow-up of positive results on fecal blood tests
 31 October 2017 
Surveillance in ulcerative colitis and Crohn’s disease
 30 October 2017 
Local recurrence after curative rectal cancer surgery
 30 October 2017 
Low-flow ascites pump in refractory cirrhosis
 30 October 2017 
Medical therapy of patients with pediatric-onset IBD
 27 October 2017 
NAFLD in advanced fibrosis in the USA
 27 October 2017 
Early readmission in cirrhosis after bacterial infections
 26 October 2017 
Predicting response to anti-TNF therapy in Crohn's

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2017 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us